Lixte Total Current Liabilities from 2010 to 2025
| LIXT Stock | USD 1.27 0.02 1.60% |
Total Current Liabilities | First Reported 2006-03-31 | Previous Quarter 329 K | Current Value 318.3 K | Quarterly Volatility 101.1 K |
Check Lixte Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lixte Biotechnology's main balance sheet or income statement drivers, such as Other Operating Expenses of 2.7 M, Total Operating Expenses of 2.7 M or Depreciation And Amortization of 6.1 M, as well as many indicators such as Price To Sales Ratio of 56.09, Dividend Yield of 2.0E-4 or PTB Ratio of 5.8. Lixte financial statements analysis is a perfect complement when working with Lixte Biotechnology Valuation or Volatility modules.
Lixte | Total Current Liabilities |
Latest Lixte Biotechnology's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Lixte Biotechnology Holdings over the last few years. Total Current Liabilities is an item on Lixte Biotechnology balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Lixte Biotechnology Holdings are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Lixte Biotechnology's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lixte Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Lixte Total Current Liabilities Regression Statistics
| Arithmetic Mean | 274,111 | |
| Geometric Mean | 235,492 | |
| Coefficient Of Variation | 32.31 | |
| Mean Deviation | 60,963 | |
| Median | 293,663 | |
| Standard Deviation | 88,571 | |
| Sample Variance | 7.8B | |
| Range | 382.3K | |
| R-Value | 0.38 | |
| Mean Square Error | 7.2B | |
| R-Squared | 0.14 | |
| Significance | 0.15 | |
| Slope | 7,042 | |
| Total Sum of Squares | 117.7B |
Lixte Total Current Liabilities History
About Lixte Biotechnology Financial Statements
Lixte Biotechnology shareholders use historical fundamental indicators, such as Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Lixte Biotechnology investors may analyze each financial statement separately, they are all interrelated. The changes in Lixte Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Lixte Biotechnology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 318.3 K | 293.7 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.